The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

Genetic Risk and Outcome of Psychosis (GROUP) investigators

doi:10.1016/j.euroneuro.2022.08.003

The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

Genetic Risk and Outcome of Psychosis (GROUP) investigators

Psychosis Studies

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.

Original language	English
Pages (from-to)	47-59
Number of pages	13
Journal	European Neuropsychopharmacology
Volume	63
DOIs	https://doi.org/10.1016/j.euroneuro.2022.08.003
Publication status	Published - Oct 2022

Keywords

Cannabis
Cognition
Cognitive dysfunction
Emotion recognition
Facial expression
Psychosis

Access to Document

10.1016/j.euroneuro.2022.08.003

Cite this

@article{de490b3c323c4a678c57b8cf0925eee1,

title = "The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study",

abstract = "Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.",

keywords = "Cannabis, Cognition, Cognitive dysfunction, Emotion recognition, Facial expression, Psychosis",

author = "{Genetic Risk and Outcome of Psychosis (GROUP) investigators} and Laura Fusar-Poli and Pries, {Lotta Katrin} and {van Os}, Jim and Rajiv Radhakrishnan and Pen{\c c}e, {Ay{\c s}eg{\"u}l Yay} and Gamze Erzin and Philippe Delespaul and Gunter Kenis and Luykx, {Jurjen J.} and Lin, {Bochao D.} and Berna Akdede and Tolga Binbay and Vesile Altınyazar and Berna Yalın{\c c}etin and G{\"u}vem G{\"u}m{\"u}{\c s}-Akay and Bur{\c c}in Cihan and Haldun Soyg{\"u}r and Halis Ula{\c s} and Cankurtaran, {Eylem {\c S}ahin} and Kaymak, {Semra Ulusoy} and Mihaljevic, {Marina M.} and Sanja Andric-Petrovic and Tijana Mirjanic and Miguel Bernardo and Gisela Mezquida and Silvia Amoretti and Julio Bobes and Saiz, {Pilar A.} and Garc{\'i}a-Portilla, {Maria Paz} and Julio Sanjuan and Aguilar, {Eduardo J.} and Santos, {Jos{\'e} Luis} and Estela Jim{\'e}nez-L{\'o}pez and Manuel Arrojo and Angel Carracedo and Gonzalo L{\'o}pez and Javier Gonz{\'a}lez-Pe{\~n}as and Mara Parellada and Maric, {Nadja P.} and Cem Atba{\c s}oğlu and Alp {\"U}{\c c}ok and K{\"o}ksal Alptekin and Saka, {Meram Can} and Eugenio Aguglia and Celso Arango and Rutten, {Bart PF} and Sinan Guloksuz",

note = "Funding Information: The EUGEI project was supported by the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2–2009–241909 (Project EU-GEI). Dr Pries is supported by the Kootstra Talent Fellowship of Maastricht University. Dr Erzin is supported by the Scientific and Technological Research Council of Turkey, 2219 International Postdoctoral Research Fellowship Program. Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); Fundaci{\'o}n Familia Alonso and Fundaci{\'o}n Alicia Koplowitz. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = oct,

doi = "10.1016/j.euroneuro.2022.08.003",

language = "English",

volume = "63",

pages = "47--59",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

}

TY - JOUR

T1 - The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls

T2 - Results from the EUGEI study

AU - Genetic Risk and Outcome of Psychosis (GROUP) investigators

AU - Fusar-Poli, Laura

AU - Pries, Lotta Katrin

AU - van Os, Jim

AU - Radhakrishnan, Rajiv

AU - Pençe, Ayşegül Yay

AU - Erzin, Gamze

AU - Delespaul, Philippe

AU - Kenis, Gunter

AU - Luykx, Jurjen J.

AU - Lin, Bochao D.

AU - Akdede, Berna

AU - Binbay, Tolga

AU - Altınyazar, Vesile

AU - Yalınçetin, Berna

AU - Gümüş-Akay, Güvem

AU - Cihan, Burçin

AU - Soygür, Haldun

AU - Ulaş, Halis

AU - Cankurtaran, Eylem Şahin

AU - Kaymak, Semra Ulusoy

AU - Mihaljevic, Marina M.

AU - Andric-Petrovic, Sanja

AU - Mirjanic, Tijana

AU - Bernardo, Miguel

AU - Mezquida, Gisela

AU - Amoretti, Silvia

AU - Bobes, Julio

AU - Saiz, Pilar A.

AU - García-Portilla, Maria Paz

AU - Sanjuan, Julio

AU - Aguilar, Eduardo J.

AU - Santos, José Luis

AU - Jiménez-López, Estela

AU - Arrojo, Manuel

AU - Carracedo, Angel

AU - López, Gonzalo

AU - González-Peñas, Javier

AU - Parellada, Mara

AU - Maric, Nadja P.

AU - Atbaşoğlu, Cem

AU - Üçok, Alp

AU - Alptekin, Köksal

AU - Saka, Meram Can

AU - Aguglia, Eugenio

AU - Arango, Celso

AU - Rutten, Bart PF

AU - Guloksuz, Sinan

N1 - Funding Information: The EUGEI project was supported by the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2–2009–241909 (Project EU-GEI). Dr Pries is supported by the Kootstra Talent Fellowship of Maastricht University. Dr Erzin is supported by the Scientific and Technological Research Council of Turkey, 2219 International Postdoctoral Research Fellowship Program. Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); Fundación Familia Alonso and Fundación Alicia Koplowitz. Publisher Copyright: © 2022

PY - 2022/10

Y1 - 2022/10

N2 - Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.

AB - Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.

KW - Cannabis

KW - Cognition

KW - Cognitive dysfunction

KW - Emotion recognition

KW - Facial expression

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=85138531826&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2022.08.003

DO - 10.1016/j.euroneuro.2022.08.003

M3 - Article

C2 - 36055075

AN - SCOPUS:85138531826

SN - 0924-977X

VL - 63

SP - 47

EP - 59

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this